- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Strides Pharma Science Limited — Updates, 30-01-2026: Press Release
30-01-2026 | 12:53 pm
30-01-2026 | 12:53 pm
Strides Pharma reported its highest ever quarterly EBITDA of 235.9 Cr. Operational PAT surged 39% YoY to 128.2 Cr. Revenue grew 3.6% to 1,194.6 Cr, driven by strong Ex-US business ($64m, +20% YoY), offsetting flat US operations. Margins expanded; a new US CEO was appointed.
No comments yet. Be the first to comment!